By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Emergent BioSolutions 

400 Professional Drive
Suite 400
Gaithersburg  Maryland  20879  U.S.A.
Phone: 240-631-3200 Fax: 240-631-3203

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.

Key Statistics

Ownership: Public

Web Site: Emergent BioSolutions
Symbol: EBS

Company News
Emergent BioSolutions (EBS) Reports Second Quarter And Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance 8/4/2017 11:25:03 AM
Emergent BioSolutions (EBS) Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense 8/1/2017 10:19:32 AM
Valneva And Emergent BioSolutions (EBS) Join Forces To Develop A Vaccine Against The Zika Virus 7/27/2017 11:37:38 AM
Emergent BioSolutions (EBS) To Release Second Quarter 2017 Financial Results And Conduct A Conference Call On August 3, 2017 7/20/2017 11:58:22 AM
Emergent BioSolutions (EBS) Pays $96 Million for GlaxoSmithKline (GSK)'s Anthrax Treatment, Will Move Manufacturing to Baltimore 7/20/2017 6:38:50 AM
Emergent BioSolutions (EBS) Buys Smallpox Vaccine Assets From Sanofi (SNY) in $125 Million Deal 7/14/2017 5:41:49 AM
Emergent BioSolutions (EBS) To Hold Annual Meeting Of Stockholders Thursday May 25, 2017 At 9:00 AM EDT; Webcast Will Be Available 5/11/2017 11:25:20 AM
Emergent BioSolutions (EBS) Unveils Its Expanded Center For Innovation In Advanced Development And Manufacturing In Baltimore 5/10/2017 8:44:35 AM
Emergent BioSolutions (EBS) To Unveil Its Expanded Center For Innovation In Advanced Development And Manufacturing Supported Through Public-Private Partnership With BARDA 5/9/2017 10:44:58 AM
Emergent BioSolutions (EBS) Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance 5/5/2017 11:40:36 AM